How We Should Rethink the Role of Technical Expertise in GMO Regulation
By Dhvani Mehta and Yashaswini Mittal,
The Wire
| 08. 31. 2015
[India]
On August 24, it was reported that the former Union Agriculture Minister, Sharad Pawar, had written to the Prime Minister recommending that he intervene to remove an existing rule that requires a no-objection certificate (NOC) from the relevant state government before field trials for genetically modified (GM) crops may be permitted. Pawar argued that the requirement of obtaining consent from state governments had become a “socio-political process rather than an objective, science-based process of rigorous evaluation at the state level” (emphasis added).
Whether or not one sides with Pawar’s view that the regulatory regime on GM crops ought to be eased, there are two fundamental problems with the statement that he offers in justification. The first assumes that the influence of social and political factors on a decision-making process that will have an impact on thousands of livelihoods and the natural environment is somehow inappropriate and undesirable. The second, which is a corollary of the first, is an unshakeable belief in the ability of science to be neutral and to guide us to the ‘correct’ decision.
Pawar is not the...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...